Core Compounds

Compound	Principal Target	Partner	Indication	Stage of Development
XL184	MET VEGFR2	Unpartnered	MTC	Phase 3
			Recurrent GBM	Phase 2
			RDT in NSCLC; SCLC; HCC; Melanoma, Breast, Ovarian, Gastric/GEJ, Pancreatic, and Prostate Cancers	Phase 2
			NSCLC + erlotinib	Phase 1b/2
			GBM + TMZ + XRT	Phase 1
			Solid Tumors	Phase 1

XL147²	PI3K	Sanofi-Aventis	Endometrial Cancer	Phase 2
			Breast Cancer + trastuzumab +/- paclitaxel	Phase 1b/2
			NSCLC + erlotinib	Phase 1b/2
			Solid Tumors + paclitaxel/carboplatin	Phase 1b/2
			Solid Tumors	Phase 1

XL765²	PI3K mTOR	Sanofi-Aventis	GBM + temozolomide	Phase 1b/2
			NSCLC + erlotinib	Phase 1b/2
			Soid Tumors	Phase 1

XL139¹	Hedgehog	Bristol-Myers Squibb	Gastric Cancer + cisplatin + capecitabine	Phase 1b
			SCLC + carboplatin + cisplatin	Phase 1b
			Multiple Myeloma + lenalidomide or bortezomib	Phase 1b
			Solid Tumors	Phase 1

XL413¹	Cdc7	Bristol-Myers Squibb	Solid Tumors	Phase 1
XL413¹	Cdc7	Bristol-Myers Squibb	Hematologic Malignancies	Phase 1

XL888	HSP90	Unpartnered	Cancer	Phase 1

XL499	PI3Kδ	Unpartnered	Cancer and Inflammation	Preclinical

In co-development agreement with BMS, Exelixis funds 35% of development costs (except for Japan) and will share 50% of any future profits from future Unites States sales and will be eligible for milestones and royalties from future ex-Unites States sales.
Out-licensed to Sanofi-Aventis. Exelixis currently conducts the majority of clinical development but is reimbursed for 100% of its costs and is eligible to receive milestones and royalties on future product sales.

XL184